Immunotherapy of Metastasizing Renal Cell Carcinoma
作者:
T. Schärfe,
S. Müller,
H. Riedmiller,
G.H. Jacobi,
R. Hohenfellner,
期刊:
Urologia Internationalis
(Karger Available online 1989)
卷期:
Volume 44,
issue 1
页码: 1-4
ISSN:0042-1138
年代: 1989
DOI:10.1159/000281439
出版商: S. Karger AG
关键词: Immunotherapy;Renal cell Carcinoma;Autologous tumor cells;vaccination with
数据来源: Karger
摘要:
119 patients with stage-IV renal cell carcinoma were treated using immunotherapy with autologous tumor vaccine. The immunization was carried out at monthly intervals, the patients were restaged every 3 months using X-ray, ultrasound scanning or computed tomography as well as bone scintigraphy in the follow-up. The patients’ follow-up periods run from 6 to 66 months averaging in 38.5 months. 6 complete remissions, 4 partial responses and 29 stable diseases were seen, whereas 54 patients had progressive disease. Patients with a T1 primary tumor all survived the follow-up period irrespective of whether lymph node metastases (n = 2), venous invasion (n = 12) or distant metastases (n = 6) were present at the time of operation. Follow-up periods run from 12 to 48 months (averaging 23 months). Patients with T2 tumors showed survival up to 50 months postoperatively, of these only 3 died. Follow-up averages 30 months. The 3 patients died within the first year after operation. Patients with very large primary tumors showed the poor prognosis normally expected. 23 of these 40 patients died after a mean follow-up of 15 months. These results may indicate that immunotherapy can slow down tumor progression and induce objective responses. Those patients with small primary lesions apparently benefit from the treatment even though metastases are present at the time of diagnosis.
点击下载:
PDF
(1687KB)
返 回